ASGR1
Asialoglycoprotein receptor 1
As of the edition of 20 October 2026, ASGR1 (asialoglycoprotein receptor 1, UniProt P07306) has 5 drugs tested at it and 5 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07306
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 8
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Hormones; Digestive system; Heart and blood vessels; Skin and connective tissue
- Registered trials of its drugs
- 24
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lumasiran | Marketed | Phase 3 | Ends 2038 |
| Vupanorsen | Stopped | Phase 2 | none listed |
| Nedosiran sodium | Marketed | Phase 3 | Ends 2038 |
| Nedosiran | Marketed | Phase 2 | none listed |
| AMG 529 | Went quiet | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Akcea Therapeutics | Route A |
| Alnylam Pharmaceuticals | Route B |
| Novo Nordisk | Route B |
The other 2 companies at ASGR1
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at ASGR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.